High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19

Mirko Scordio, Federica Frasca, Letizia Santinelli, Leonardo Sorrentino, Alessandra Pierangeli, Ombretta Turriziani, Claudio M. Mastroianni, Guido Antonelli, Raphael P. Viscidi, Gabriella d'Ettorre, Carolina Scagnolari

Research output: Contribution to journalLetterpeer-review

Abstract

The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients.

Original languageEnglish (US)
Article number109068
JournalClinical Immunology
Volume241
DOIs
StatePublished - Aug 2022

Keywords

  • HIV-1
  • HIV-1 and SARS-CoV-2 co-infection
  • ISGs
  • Interferon
  • Neutralizing antibodies
  • SARS-CoV-2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19'. Together they form a unique fingerprint.

Cite this